Disclosed herein are surgical staple line reinforcement materials and methods of production and use thereof.

Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a body cavity and placed in contact with, for example, tissue, injured tissue, internal organs, etc. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in situ foam formation). In addition, the foamed polymers may be capable of exerting a pressure on an internal surface of a body cavity and preventing or limiting movement of a bodily fluid (e.g., blood, etc.).

In one aspect, the present invention includes a haemostat composition that includes a chitosan, chitosan salt or chitosan derivative, and a physiologically acceptable acid selected from the group consisting of lactic acid, formic acid, acetic acid, ascorbic acid, halogen acetic acids, propanoic acid, propenoic acid, acrylic acid, glyoxylic acid, pyruvic acid or a hydroxy propionic/butanoic acid, and combinations of any two or more thereof; or one or more acids selected from hydrochloric acid and sulphuric acid. The haemostat composition is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.

A hemostatic composition comprises a powder of a plurality of hollow or highly-porous microparticles that exhibit hemostatic properties, wherein each of the microparticles comprise a body comprising a clay material that is a crystalline hydrated form of a layered silicate.

Systems, methods and compositions relating to delivering synthetic polymer formulations to the body are described, which can be used by a range of medical personnel including those with minimal experience and training. Under some embodiments, the present invention relates to systems and devices for delivering polymer formulations to a body cavity (e.g. peritoneal cavity) to reduce or stop bleeding. Under some embodiments, an initial percutaneous access pathway is first formed using a delivery device with a probe and needle mechanism that automatically stops the advance of the device upon insertion into a body cavity or space, thus minimizing user error and improving patient safety. The hollow probe then allows transmission of polymer, mixed with gas and/or additional substances, from a holding chamber or canister to flow through the device and hollow probe into the patient's anatomic cavity or space of interest, stopping expansion when the device senses the appropriate pressure. Once reaching the body cavity, the polymer formulation functions to reduce and/or stop bleeding.

Disclosed is absorbable bone wax and a preparation method thereof. The preparation method comprises the steps of: 1) mixing polyoxypropylene polyoxyethylene block copolymer (PEG-PPG-PEG) and polyoxypropylene polyoxyethylene random copolymer (PEG-PPG), and stirring evenly under heating to obtain a liquid mixture; 2) under mechanical stirring and heating condition, adding hemostatic starch microspheres to the liquid mixture obtained in step 1) to obtain a uniformly-mixed liquid; and 3) adding a bone repair material to the uniformly-mixed liquid obtained in step 2), and mixing uniformly to obtain a mixed solution, then pouring the mixed solution into a mold or sub-packaged bottle, and leaving at room temperature for solidifying and shaping to give the absorbable bone wax. The absorbable bone wax of the present invention can achieve the effect of rapid hemostasis, changing the relatively single hemostasis method with traditional bone wax which only depends on physical sealing.

Disclosed are solid and frozen haemostatic materials having a rod shape and suitable applicators and plungers for application of such dressings to wounded tissue wherein said dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques.

An adhesive material that provides fast and robust adhesion on wet surfaces, where the adhesion formed is detachable on-demand. The adhesive material is formed of one or more hydrophilic polymers or copolymers grafted with one or more amine coupling groups via a plurality of cleavable physical bonds and/or cleavable covalent bonds and one or more cross linkers. Application of the adhesive material on a wet surface causes the adhesive material to absorb liquid to thereby swell the adhesive material to form a layer of hydrogel, resulting in the formation of temporary crosslinks followed by covalent crosslinks with the surface. Introducing a triggering agent cleaves the cleavable physical bonds and/or cleavable covalent bonds to allow for non-traumatic detachment of the adhesive material from the surface.

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer.

The present invention provides a method for removing an organic solvent from starch hemostatic microspheres, comprising the following steps: 1. taking to-be-dried starch hemostatic microspheres and laying them flatly on drying trays with attention to laying them as uniformly and thinly as possible; 2. taking an adsorbent and subpackaging it into dialyzing paper bags for sealing; and 3. placing the trays and the dialyzing paper bags completed in the previous two steps on separators of a low-temperature vacuum oven in layers, setting the oven temperature at 0-20° C., then vacuumizing and keeping pressure for 15-48 hours. The method provided by the present invention can reduce organic solvent residue in the starch hemostatic microspheres to less than 0.05%, which meets the requirements of relevant standards for medical devices, thereby improving safety of products.